Disparate distribution of 16 candidate single nucleotide polymorphisms among racial and ethnic groups of pediatric heart transplant patients

Transplantation

Volumn 82, Issue 12, 2006, Pages 1774-1780

  Girnita, Diana M ^a   Webber, Steven A ^a   Ferrell, Robert ^b   Burckart, Gilbert J ^c   Brooks, Maria M ^d   McDade, Kevin K ^a   Chinnock, Richard ^e   Canter, Charles ^f   Addonizio, Linda ^g   Bernstein, Daniel ^h   Kirklin, James K ⁱ   Girnita, Alin L ^a   Zeevi, Adriana ^a,j  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e LOMA LINDA UNIVERSITY   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Och Spine at New York Presbyterian Hospitals   (United States)

^h STANFORD UNIVERSITY   (United States)

ⁱ Kentucky   (United States)

^j NONE   (United States)

more..

Author keywords

African American; Gene polymorphism; Heart; Hispanic; Multicenter studies; Pediatric; Transplantation

Indexed keywords

CYTOCHROME P450 3A5; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 10; INTERLEUKIN 6; MULTIDRUG RESISTANCE PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADOLESCENT; ADULT; AFRICAN AMERICAN; CAUCASIAN; CHILD; CONFERENCE PAPER; CONTROLLED STUDY; DNA POLYMORPHISM; ETHNIC GROUP; FEMALE; GENE; GENE EXPRESSION; GENE FREQUENCY; GENOTYPE; GRAFT RECIPIENT; HEART GRAFT; HEART TRANSPLANTATION; HETEROZYGOTE; HISPANIC; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RACE; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CONTINENTAL POPULATION GROUPS; CYTOKINES; ETHNIC GROUPS; FEMALE; HEART TRANSPLANTATION; HUMANS; INFANT; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 33845917818     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000250656.33731.08     Document Type: Conference Paper

References (45)

1. Mahle WT, Kanter KR, Vincent RN. Disparities in outcome for black patients after pediatric heart transplantation. J Pediatr 2005; 147(6): 739.
2. Chin C, Naftel DC, Singh TP, et al. Risk factors for recurrent rejection in pediatric heart transplantation: a multicenter experience. J Heart Lung Transplant 2004; 23(2): 178.
3. Gupta P, Hart J, Cronin D, et al. Risk factors for chronic rejection after pediatric liver transplantation. Transplantation 2001; 72(6): 1098.
4. Benfield MR, McDonald R, Sullivan EK, et al. The 1997 Annual Renal Transplantation in Children Report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 1999; 3(2): 152.
5. Sun T, Miao X, Zhang X, et al. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 2004; 96(13): 1030.
6. Brogan IJ, Khan N, Isaac K, et al. Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor gene. Hum Immunol 1999; 60(12): 1245.
7. Stevens A, Soden J, Brenchley PE, et al. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 2003; 63(4): 812.
8. Zheng H, Webber S, Zeevi A, et al. The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum Immunol 2002; 63(9): 765.
9. Zheng HX, Webber SA, Zeevi A, et al. The impact of pharmacogenomic factors on steroid dependency in pediatric heart transplant patients using logistic regression analysis. Pediatr Transplant 2004; 8(6): 551.
10. Turner DM, Williams DM, Sankaran D, et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24(1): 1.
11. Shahbazi M, Fryer AA, Pravica V, et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 2002; 13(1): 260.
12. Wilson AG, Symons JA, McDowell TL, et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A 1997; 94(7): 3195.
13. Baseggio L, Bartholin L, Chantome A, et al. Allele-specific binding to the -308 single nucleotide polymorphism site in the tumour necrosis factor-alpha promoter. Eur J Immunogenet 2004; 31(1): 15.
14. Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 1997; 34(5): 391.
15. Turner D, Grant SC, Yonan N, et al. Cytokine gene polymorphism and heart transplant rejection. Transplantation 1997; 64(5): 776.
16. Ternstrom L, Jeppsson A, Ricksten A, Nilsson F. Tumor necrosis factor gene polymorphism and cardiac allograft vasculopathy. J Heart Lung Transplant 2005; 24(4): 433.
17. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102(7): 1369.
18. Pravica V, Perrey C, Stevens A, et al. A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Hum Immunol 2000; 61(9): 863.
19. Rossouw M, Nel HJ, Cooke GS, et al. Association between tuberculosis and a polymorphic NFkappaB binding site in the interferon gamma gene. Lancet 2003; 361(9372): 1871.
20. Hoffmann SC, Stanley EM, Cox ED, et al. Ethnicity greatly influences cytokine gene polymorphism distribution. Am J Transplant 2002; 2(6): 560.
21. Delaney NL, Esquenazi V, Lucas DP, et al. TNF-alpha, TGF-beta, IL-10, IL-6, and INF-gamma alleles among African Americans and Cuban Americans. Report of the ASHI Minority Workshops: Part IV. Hum Immunol 2004; 65(12): 1413.
22. Hutchings A, Guay-Woodford L, Thomas JM, et al. Association of cytokine single nucleotide polymorphisms with B7 costimulatory molecules in kidney allograft recipients. Pediatr Transplant 2002; 6(1): 69.
23. Ho AS, Moore KW. Interleukin-10 and its receptor. Ther Immunol 1994; 1(3): 173.
24. Awad MR, Webber S, Boyle G, et al. The effect of cytokine gene polymorphisms on pediatric heart allograft outcome. J Heart Lung Transplant 2001; 20(6): 625.
25. Mazariegos GV, Reyes J, Webber SA, et al. Cytokine gene polymorphisms in children successfully withdrawn from immunosuppression after liver transplantation. Transplantation 2002; 73(8): 1342.
26. Zheng HX, Burckart GJ, McCurry K, et al. Interleukin-10 production genotype protects against acute persistent rejection after lung transplantation. J Heart Lung Transplant 2004; 23(5): 541.
27. Warle MC, Metselaar HJ, Hop WC, Tilanus HW. Cytokine gene polymorphisms and acute liver graft rejection: a meta-analysis. Liver Transpl 2005; 11(1): 19.
28. Sankaran D, Asderakis A, Ashraf S, et al. Cytokine gene polymorphisms predict acute graft rejection following renal transplantation. Kidney Int 1999; 56(1): 281.
29. Aziz T, Hasleton P, Hann AW, et al. Transforming growth factor beta in relation to cardiac allograft vasculopathy after heart transplantation. J Thorac Cardiovasc Surg 2000; 119(4 Pt 1): 700.
30. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997; 34(8 -9): 577.
31. Kanemitsu S, Ihara K, Saifddin A, et al. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol 2002; 29(6): 1183.
32. Oh SI, Kim IW, Jung HC, et al. Correlation of Fas and Fas ligand expression with rejection status of transplanted heart in human. Transplantation 2001; 71(7): 906.
33. Wu J, Metz C, Xu X, et al. A novel polymorphic CAAT/enhancerbinding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol 2003; 170(1): 132.
34. Shulzhenko N, Morgun A, Zheng XX, et al. Intragraft activation of genes encoding cytotoxic T lymphocyte effector molecules precedes the histological evidence of rejection in human cardiac transplantation. Transplantation 2001; 72(10): 1705.
35. Zeevi A, Pavlakis M, Spichty K, et al. Prediction of rejection in lung transplantation. Transplant Proc 2001; 33(1-2): 291.
36. Bittmann I, Muller C, Behr J, et al. Fas/FasL and perforin/granzyme pathway in acute rejection and diffuse alveolar damage after allogeneic lung transplantation-a human biopsy study. Virchows Arch 2004; 445(4): 375.
37. Netto MV, Fonseca BA, Dantas M, et al. FAS-ligand and perforin expression during acute cellular rejection episodes after kidney transplantation: comparison between blood and renal aspirates. Transplant Proc 2002; 34(2): 476.
38. Torry RJ, Bai L, Miller SJ, et al. Increased vascular endothelial growth factor expression in human hearts with microvascular fibrin. J Mol Cell Cardiol 2001; 33(1): 175.
39. Reinders ME, Sho M, Izawa A, et al. Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest 2003; 112(11): 1655.
40. Lemstrom KB, Krebs R, Nykanen AI, et al. Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis. Circulation 2002; 105(21): 2524.
41. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97(7): 3473.
42. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27(4): 383.
43. Floyd MD, Gervasini G, Masica AL, et al. Genotype-phenotype associations forcommonCYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 2003; 13(10): 595.
44. Zheng H, Webber S, Zeevi A, et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 2003; 3(4): 477.
45. Zheng HX, Zeevi A, McCurry K, et al. The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients. Transpl Immunol 2005; 14(1): 37.